We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Crystal Structure of CARDS Toxin Expected to Advance Respiratory Disease Treatment

By LabMedica International staff writers
Posted on 20 Apr 2015
Print article
Image: Molecular model of CARDS toxin, which was first described in 2006 (Photo courtesy of the University of Texas Health Science Center at San Antonio).
Image: Molecular model of CARDS toxin, which was first described in 2006 (Photo courtesy of the University of Texas Health Science Center at San Antonio).
A recent paper described the molecular structure of Mycoplasma pneumoniae's Community Acquired Respiratory Distress Syndrome (CARDS) toxin and explained how knowing this structure may lead to advances in the prevention and treatment of diseases caused by this respiratory pathogen.

Mycoplasma pneumoniae is a very small bacterium in the class Mollicutes. It is a human pathogen that causes the disease mycoplasma pneumonia, a form of atypical bacterial pneumonia related to cold agglutinin disease. The organism is characterized by the absence of a peptidoglycan cell wall and resulting resistance to many antibacterial agents. As part of the infectious process, the bacterium expresses the 591-amino acid long CARDS toxin virulence factor with both mono-ADP ribosyltransferase (mART) and vacuolating activities. CARDS toxin binds to human surfactant protein A and annexin A2 on airway epithelial cells and is internalized, leading to a range of pathological genetic events.

In a paper published in the April 7, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) investigators at the University of Texas Health Science Center (San Antonio, USA) presented the X-ray crystallography-derived structure of CARDS toxin. The results depicted a triangular molecule in which N-terminal mART and C-terminal tandem beta-trefoil domains associated to form an overall architecture distinct from other well-recognized ADP-ribosylating bacterial toxins. The investigators demonstrated that CARDS toxin bound phosphatidylcholine and sphingomyelin specifically over other membrane lipids, and that cell surface binding and internalization activities were housed within the C-terminal beta-trefoil domain.

Recombinant CARDS toxin administered to naive mice induced an allergic-type inflammatory response and airway hyperreactivity, suggesting that an analogous response in humans might play a causal role in M. pneumoniae-associated asthma.

"We know a lot about how the toxin works, but we did not have its three-dimensional structure," said contributing author Dr. Joel B. Baseman, professor of microbiology and immunology at the University of Texas Health Science Center. "The structure shows us the molecular architecture of the protein, which permits the rational design of effective drugs and vaccines to neutralize the injurious effects of CARDS toxin. Blocking the toxin could prove to be a major advance in the prevention and care of a wide range of acute and chronic airway diseases."

Related Links:

University of Texas Health Science Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.